- Stocks
- Pharma & Healthcare
- Ajanta Pharma
Ajanta Pharma share price
NSE: AJANTPHARMPharma & HealthcareDrug Manufacturers - Specialty & Generic
Ajanta Pharma at a glance
Ajanta Pharma (NSE: AJANTPHARM) closed at ₹3,260.00 on 22 Oct 2026, up 0.00% on the day. With a market capitalisation of ₹40,861 Cr, it ranks 221st by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 38.6× trailing earnings, against a return on equity of 23.3% in FY26. Over the past year the share price has risen 36.1%. Its 52-week range is ₹2,382.00 (28 Oct 2025) to ₹3,796.00 (18 Aug 2026); the last close is 14.1% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹1,626 Cr (+24.8% year on year) and net profit ₹334 Cr (+30.9%), on a consolidated basis. Promoters held 63.48% of the company as of 30 Jun 2026; 22.53% of promoter shares were pledged.
Key numbers
- Market cap
- ₹40,861 CrRank 221 on NSE
- P/E (trailing)
- 38.6×
- Price to book
- 7.76×FY26
- EPS (TTM)
- ₹90.84to Q1 FY27
- ROE
- 23.3%FY26
- ROCE
- 29.4%FY26
- Debt to equity
- 0.05FY26
- Net profit margin
- 19.4%FY26
- Book value / share
- ₹361.16FY26
- Dividend payout
- 28.5%FY26
- 52-week high
- ₹3,796.0018 Aug 2026
- 52-week low
- ₹2,382.0028 Oct 2025
- 1-year return
- +36.1%
- RSI (14-day)
- 31.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | 0.00% | −2.1% | −7.4% | −5.8% | +36.1% |
Ajanta Pharma quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,187 Cr | ₹1,146 Cr | ₹1,170 Cr | ₹1,303 Cr | ₹1,354 Cr | ₹1,375 Cr | ₹1,422 Cr | ₹1,626 Cr |
| Revenue YoY | +15.4% | +3.7% | +11.0% | +13.8% | +14.1% | +20.0% | +21.5% | +24.8% |
| Net profit | ₹216 Cr | ₹233 Cr | ₹225 Cr | ₹255 Cr | ₹260 Cr | ₹274 Cr | ₹267 Cr | ₹334 Cr |
| Net profit YoY | +10.8% | +10.9% | +11.1% | +3.9% | +20.2% | +17.6% | +18.4% | +30.9% |
| Net margin | 18.2% | 20.3% | 19.2% | 19.6% | 19.2% | 19.9% | 18.8% | 20.6% |
| EPS | ₹17.27 | ₹18.60 | ₹18.00 | ₹20.44 | ₹20.83 | ₹21.91 | ₹21.35 | ₹26.75 |
Ajanta Pharma financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹2,890 Cr | ₹3,341 Cr | ₹3,743 Cr | ₹4,209 Cr | ₹4,648 Cr | — |
| Operating profit | ₹900 Cr | ₹909 Cr | ₹745 Cr | ₹1,114 Cr | ₹1,189 Cr | — |
| Net profit | ₹654 Cr | ₹713 Cr | ₹588 Cr | ₹816 Cr | ₹920 Cr | — |
| EPS (₹) | ₹75.00 | ₹82.00 | ₹46.00 | ₹65.00 | ₹74.00 | — |
| Cash from operations | ₹576 Cr | ₹562 Cr | ₹792 Cr | ₹785 Cr | ₹1,157 Cr | — |
| Total debt | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹2,996 Cr | ₹3,264 Cr | ₹3,388 Cr | ₹3,567 Cr | ₹3,790 Cr | ₹4,527 Cr |
Ajanta Pharma shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 66.26% | 66.26% | 66.25% | 66.25% | 66.25% | 63.48% |
| Foreign institutions | 8.86% | 8.86% | 8.53% | 7.98% | 8.26% | 7.68% |
| Domestic institutions | 17.48% | 17.50% | 17.90% | 18.58% | 18.37% | 21.80% |
| Non-institutions | 7.39% | 7.38% | 7.32% | 7.19% | 7.12% | 7.03% |
| Promoter shares pledged | 12.61% | 14.43% | 15.28% | 17.29% | 17.94% | 22.53% |
Ajanta Pharma vs peers
The listed Pharma & Healthcare companies nearest to Ajanta Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| IPCALABIPCA Laboratories | ₹1,932.90 | +0.62% | +48.4% | ₹48,293 Cr | 43 | 14.2% |
| GLANDGland Pharma | ₹2,910.60 | −0.66% | +52.0% | ₹47,020 Cr | 46.7 | 9.9% |
| ANTHEMAnthem Biosciences | ₹802.40 | −0.52% | +3.0% | ₹45,113 Cr | 76.6 | 19.4% |
| GLAXOGlaxoSmithKline Pharmaceuticals | ₹2,455.20 | +0.17% | −9.1% | ₹41,228 Cr | 40.1 | 47.7% |
| AJANTPHARMAjanta Pharma | ₹3,260.00 | 0.00% | +36.1% | ₹40,861 Cr | 38.6 | 23.3% |
| NHNarayana Hrudayalaya | ₹1,691.90 | −2.21% | −2.8% | ₹34,602 Cr | 42.4 | 17.8% |
| EMCUREEmcure Pharmaceuticals | ₹1,759.20 | +0.09% | +31.6% | ₹33,812 Cr | 145.1 | 18.7% |
Ask anything about Ajanta Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against AJANTPHARM's own history. Try: “Why has AJANTPHARM moved over the last three months?” · “Backtest a 50-day moving-average crossover on AJANTPHARM over five years” · “Compare AJANTPHARM with IPCALAB on margins and valuation”
Frequently asked questions about Ajanta Pharma
What is the share price of Ajanta Pharma today?
Ajanta Pharma (NSE: AJANTPHARM) last closed at ₹3,260.00 on 22 Oct 2026. Its 52-week high is ₹3,796.00 and its 52-week low is ₹2,382.00.
What is the market cap of Ajanta Pharma?
Ajanta Pharma's market capitalisation is ₹40,861 Cr (₹40,861 Cr) at the 22 Oct 2026 close, ranking 221st among the NSE companies Pivot tracks.
What is the P/E ratio of Ajanta Pharma?
Ajanta Pharma trades at a trailing P/E of 38.6. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 46.7.
What is the ROE and ROCE of Ajanta Pharma?
Return on equity was 23.3% in FY26 and return on capital employed was 29.4% in FY26 (consolidated figures).
Is Ajanta Pharma a debt-free company?
Ajanta Pharma is close to debt-free: its debt-to-equity ratio was 0.05 in FY26.
What were Ajanta Pharma's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Ajanta Pharma reported revenue of ₹1,626 Cr, +24.8% year on year, and net profit of ₹334 Cr, +30.9% year on year.
How has Ajanta Pharma stock performed over the last year?
Ajanta Pharma's share price has risen 36.1% over the past year, −5.8% over three months and −7.4% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Ajanta Pharma?
As of 30 Jun 2026: promoters 63.48%, foreign institutions 7.68%, domestic institutions 21.80%, non-institutions 7.03%. 22.53% of promoter shares were pledged.
Who are Ajanta Pharma's competitors?
The listed Pharma & Healthcare companies closest to Ajanta Pharma by market cap are IPCA Laboratories, Gland Pharma, Anthem Biosciences, GlaxoSmithKline Pharmaceuticals, Narayana Hrudayalaya and Emcure Pharmaceuticals.
Is Ajanta Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Ajanta Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AJANTPHARM against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text